Introducing Hayat Pharmaceutical Industries
Hayat Pharmaceutical Industries® (hPI) was established in 1994 by a group of pharmacists with a vision to provide high quality pharmaceutical products to the global market.
Hayat Pharmaceutical Industries, based in Amman, the capital city of Jordan, is a relatively young pharmaceutical manufacturer and marketer founded on a wealth of experience in the field of marketing and distribution of pharmaceuticals.
Dr. Mohammad Ali Kurdi, a passionate entrepreneur, noted a window of opportunity for the manufacture of generic pharmaceuticals in Jordan and the potential of a large export market to the Middle East and North Africa region. Jordan had integrated itself into the global market by joining the WTO. HPI therefore set its sights on EU countries and Eastern Europe.
HPI is a limited liability, private share-holding company. Dr. Maher Kurdi acts as chairman and Managing Director® (m.D). HPI team members are quality conscious professionals with long experience in their fields. Currently the HPI team consists of 99 employees with the following qualifications.
|Post-graduate degrees® (ph.D., Masters, and High diploma )||7%|
|High school or less||30%|
The company operates out of a state-of-the-art, 8000 square meter production facility located on the outskirts of Amman. The plant produces a wide range of pharmaceutical dosage forms with strict adherence to current Good Manufacturing Practice® (cGMP) guidelines and the implementation of a Quality Assurance system that ensures high quality product output.
The plant facilities include three production lines covering three categories. These include solid dosage forms such as tablets, capsules and dry suspensions; semi-solid dosage forms such as creams, ointments, suppositories and gels; and liquid dosage forms such as syrups, nasal and ear-drops and other solutions.
Production in the HPI plant started in 1996 followed in the next year by the launch of the first products to the local market. Currently, and only four years later, HPI operates in 11 different countries throughout the Middle East and North Africa, and has licensing agreements with two European companies.
HPI has developed and registered 116 products of different molecules and in various therapeutic areas. There are more than 56 products in the market now.
HPI obtained European GMP approval of its plant for future expansion in the EU market.